Search

Your search keyword '"Portielje, Johanneke E.A."' showing total 143 results

Search Constraints

Start Over You searched for: Author "Portielje, Johanneke E.A." Remove constraint Author: "Portielje, Johanneke E.A."
143 results on '"Portielje, Johanneke E.A."'

Search Results

2. Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial

11. Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study

13. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study

15. Patient and physician shared decision-making behaviors in oncology: Evidence on adequate measurement properties of the iSHARE questionnaires

18. Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer

24. Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis.

27. Supplementary Figure from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

28. Supplementary Table from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

29. Supplementary Data from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

31. Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

32. Patient and physician shared decision-making behaviors in oncology: Evidence on adequate measurement properties of the iSHARE questionnaires

34. Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands – A comparison of two national prospective longitudinal multi-centre cohort studies

35. Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2 + Metastatic Breast Cancer: HERTAX Trial

36. Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

37. Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial*

41. Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison

42. Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy

45. Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy

47. Omission of surgery in elderly patients with early stage breast cancer

48. Lack of Survival Gain for Elderly Women with Breast Cancer

49. Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRASmutant metastatic colorectal cancer patients

Catalog

Books, media, physical & digital resources